Journal
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
Volume 10, Issue 4, Pages 431-442Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2016.1140571
Keywords
pharmacokinetics; pharmacodynamics; irritable bowel syndrome; diarrhea; gut microbiota; Rifaximin
Categories
Funding
- National Institute for Health Research [ACF-2014-02-006] Funding Source: researchfish
Ask authors/readers for more resources
Irritable bowel syndrome (IBS) is a chronic, functional bowel disorder characterized by abdominal pain or discomfort and altered bowel habit. The pathophysiology is unclear, but may include altered gut motility, visceral hypersensitivity, abnormal central pain processing, chronic low-grade intestinal inflammation, or disturbances in the gut microbiome. These etiological mechanisms, alongside environmental factors such as stress and anxiety, vary between individuals and represent potential targets for treatment. Rifaximin is a poorly absorbed oral antibiotic proposed to act on the gut microenvironment, used in the treatment of travelers' diarrhea and hepatic encephalopathy. Clinical trials suggest the drug can reduce global IBS symptoms and improve bloating, abdominal pain, and stool consistency in some patients with non-constipated IBS, leading to Food and Drug Administration approval in the United States. This article considers the pharmacology of rifaximin, the evidence for its use in IBS, and the safety and tolerability of the drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available